Improve hand dexterity with phygital
- Trial ID
- NCT07475741
- Official Title
- Exergaming With Physical Onjects for Upper Limb Rehabilitation in Parkinson's Disease: Effects on Functional Outcome
- Goal
- Improve hand dexterity with phygital
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- University of Health Sciences Lahore
- Study Type
- INTERVENTIONAL
- Enrollment
- 30 participants
- Conditions
- Parkinsons Disease (PD)
- Interventions
- Exergaming, Conventional Physical Therapy
Plain-Language Summary
The goal is to improve upper limb function and everyday hand use in people with early-stage Parkinson's, by comparing an engaging exergaming approach to conventional physical therapy. The exergaming uses interactive games that require manipulating physical objects to train strength, coordination, fine motor control and timing, a form of repetitive, task-specific practice that supports motor learning and neuroplasticity, and it is a rehabilitative approach that complements levodopa/carbidopa rather than replacing or chemically interacting with it. The trial is looking for adults 45 to 85 with Hoehn and Yahr stage I to III PD who can follow commands, have an MMSE of 24 or higher, and are on regular levodopa/carbidopa, while excluding advanced-stage disease, significant cognitive impairment, other neurologic or musculoskeletal hand problems, or use of medicines for systemic illnesses.
Locations
- Punjab institute of Neuroscience Lahore, Lahore, Punjab Province, Pakistan
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Exergaming. The goal is to improve upper limb function and everyday hand use in people with early-stage Parkinson's, by comparing an engaging exergaming approach to conventional physical therapy. The exergaming uses interactive games that require manipulating physical objects to train strength, coordination, fine motor control and timing, a form of repetitive, task-specific practice that supports motor learning and neuroplasticity, and it is a rehabilitative approach that complements levodopa/carbidopa rather than replacing or chemically interacting with it. The trial is looking for adults 45 to 85 with Hoehn and Yahr stage I to III PD who can follow commands, have an MMSE of 24 or higher, and are on regular levodopa/carbidopa, while excluding advanced-stage disease, significant cognitive impairment, other neurologic or musculoskeletal hand problems, or use of medicines for systemic illnesses.
- Who can participate?
- Participants must be between 45 Years and 85 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 6 months.